moxifloxacin has been researched along with oseltamivir in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (oseltamivir) | Trials (oseltamivir) | Recent Studies (post-2010) (oseltamivir) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,368 | 186 | 2,014 |
| Protein | Taxonomy | moxifloxacin (IC50) | oseltamivir (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.1104 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.2616 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 2.0317 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 1.1344 | |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | 0.002 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.005 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.008 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0003 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.003 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ding, C; Gao, Z; Horby, P; Jiang, G; Jiang, R; Li, R; Liu, X; Nie, C; Qian, K; Sun, J; Wan, J; Wang, Q; Xiao, Z; Zeng, Z; Zhang, J; Zhang, W | 1 |
| Liu, J; Long, X; Luo, H; Pan, X; Shen, F; Wang, S; Wu, J; Yao, L; Yuan, T | 1 |
| Tong, XC; Weng, SS; Wu, X; Xu, TM; Xue, F; Zhang, WH | 1 |
| Ding, D; Yao, W; Zhu, C | 1 |
1 review(s) available for moxifloxacin and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for moxifloxacin and oseltamivir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Clinical characteristics of human infection with a novel avian-origin influenza A(H10N8) virus.
Topics: Aged; Antiviral Agents; Female; Fluoroquinolones; Humans; Imipenem; Influenza A Virus, H10N8 Subtype; Influenza, Human; Male; Middle Aged; Moxifloxacin; Oseltamivir | 2014 |
Clinical characteristics from co-infection with avian influenza A H7N9 and Mycoplasma pneumoniae: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Coinfection; Female; Fluoroquinolones; Humans; Immunoglobulins; Influenza A Virus, H7N9 Subtype; Influenza, Human; Methylprednisolone; Moxifloxacin; Mycoplasma pneumoniae; Oseltamivir; Pneumonia, Mycoplasma | 2018 |
First human infection by a novel avian influenza A(H7N4) virus.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; China; Female; Genome, Viral; Humans; Influenza A virus; Influenza, Human; Methylprednisolone; Moxifloxacin; Oseltamivir; Radiography, Thoracic; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
A Cured Patient With 2019-nCoV Pneumonia.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Female; Humans; Moxifloxacin; Oseltamivir; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |